Pipeline
We are developing novel siRNA therapies for the treatment of cardiovascular diseases, addressing a potential market value of over 10 billion US dollars.
first-in-class
best-in-class
- Asset
- Target
- Discovery
- Preclinical
- IND Filing
- Phase Ⅰ
- Phase Ⅱ
- Phase Ⅲ
